Q1 EPS Forecast for Corcept Therapeutics Lowered by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research reduced their Q1 2026 EPS estimates for Corcept Therapeutics in a research note issued on Tuesday, March 17th. Zacks Research analyst Team now forecasts that the biotechnology company will earn ($0.35) per share for the quarter, down from their prior forecast of ($0.31). Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $0.40 EPS, FY2026 earnings at $0.20 EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at $0.18 EPS, Q3 2027 earnings at $0.91 EPS, Q4 2027 earnings at $0.77 EPS and FY2027 earnings at $1.67 EPS.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.13). The business had revenue of $202.13 million during the quarter, compared to analysts’ expectations of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the previous year, the business posted $0.26 EPS.

Several other equities analysts have also recently commented on the stock. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target for the company. in a research report on Wednesday, December 31st. Truist Financial set a $50.00 price objective on Corcept Therapeutics in a research note on Wednesday, December 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. UBS Group began coverage on Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price for the company. Finally, HC Wainwright cut their price target on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $77.17.

Corcept Therapeutics Price Performance

Shares of CORT opened at $34.64 on Friday. The company has a market cap of $3.68 billion, a P/E ratio of 42.24 and a beta of 0.29. Corcept Therapeutics has a fifty-two week low of $28.66 and a fifty-two week high of $117.33. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average price is $37.46 and its 200 day moving average price is $61.93.

Institutional Trading of Corcept Therapeutics

Institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. boosted its position in shares of Corcept Therapeutics by 438.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 65,797 shares of the biotechnology company’s stock worth $2,290,000 after acquiring an additional 53,574 shares in the last quarter. Corient Private Wealth LLC raised its position in shares of Corcept Therapeutics by 9.3% during the 4th quarter. Corient Private Wealth LLC now owns 7,035 shares of the biotechnology company’s stock worth $245,000 after acquiring an additional 600 shares in the last quarter. SHP Wealth Management acquired a new stake in shares of Corcept Therapeutics during the 4th quarter worth about $72,000. Caitong International Asset Management Co. Ltd purchased a new stake in Corcept Therapeutics during the fourth quarter worth approximately $8,757,000. Finally, Virtu Financial LLC purchased a new stake in Corcept Therapeutics during the fourth quarter worth approximately $456,000. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director G Leonard Baker, Jr. acquired 100,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, March 17th. The shares were acquired at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the acquisition, the director owned 1,146,631 shares of the company’s stock, valued at $37,999,351.34. This trade represents a 9.55% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider William Guyer sold 8,233 shares of Corcept Therapeutics stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $35.99, for a total transaction of $296,305.67. Following the sale, the insider directly owned 2,231 shares of the company’s stock, valued at approximately $80,293.69. This trade represents a 78.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 48,233 shares of company stock worth $1,817,306 over the last 90 days. Company insiders own 20.80% of the company’s stock.

Key Headlines Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Director G. Leonard Baker Jr. bought 100,000 shares (~$3.3M) at about $33.14 on March 17, a meaningful insider purchase that signals management confidence and can support short‑term demand. Read More.
• Neutral Sentiment: Short‑interest reports for March 19–20 show effectively zero reported short interest (days‑to‑cover ≈ 0), which appears anomalous and likely reflects reporting quirks rather than a genuine absence of short sellers; this creates uncertainty about short‑seller pressure signals.
• Negative Sentiment: Multiple shareholder‑rights firms (Hagens Berman, Schall, DJS, Pomerantz, Rosen, Glancy, others) have issued class‑action/lead‑plaintiff notices tied to alleged FDA issues and a federal court patent loss — a concentrated legal PR wave that raises litigation risk, could increase future liabilities, and likely weighs on investor confidence. Read More. Read More.
• Negative Sentiment: Zacks Research sharply cut EPS forecasts across 2026–2027 and maintains a “Strong Sell” stance — analyst downgrades and lower near‑term earnings expectations increase downside pressure on valuation and can amplify selling if guidance or legal exposure worsens. Read More.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.